Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer with a high mortality rate. While chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections represent the leading risk factors worldwide, the spreading of metabolic disorders, such as diabetes, obesity and non-alcoholic fatty liver disease (NAFLD) justifies the increasing attention on their oncogenic mechanisms. This review discusses about the main pathogenic mechanisms implicated in occurrence of HCC in presence of viral and metabolic diseases. Additionally, it points to the importance of clinical surveillance for those patients considered at risk of HCC and highlights the strategical role of serum markers, such as alfa-fetoprotein (αFP) and Protein Induced by Vitamin K Absence or Antagonist II (PIVKA-II), which, in association to a strictly instrumental follow-up, contribute to the early detection of hepatic nodules with a better prognosis for affected patients.
Introduction
Hepatocellular carcinoma (HCC) generally develops from a background of chronic inflammatory liver disease and, despite both the imminent disappearance of Hepatitis C Virus (HCV)-related chronic disease and the maintenance of a low or absent replication load in Hepatitis B Virus (HBV) chronic infections, It has been reported that annual risk of HCC is 0.5% and 0.8% for asymptomatic HBsAg carriers and for patients with chronic HBV disease, respectively; the effective annual risk increases by 100 times for HBV cirrhotic people [5] .
Although 70% -90% of HCC occurs in cirrhotic HBV carriers, HBV chronic infection is a well-known cause of HCC also in absence of cirrhosis ( Figure 2 ).
The risk of developing hepatocellular carcinoma in patients with persistent HBV infection is greater among males and correlates with the duration of infection, high levels of HBV viral load and infection with genotype "C" of HBV [10] .
Co-factors such as family history of HCC, exposure to mycotoxins (aflatoxin), alcohol abuse or tobacco dependence, HCV and/or HDV co-infections, greatly increase the risk of HCC [11] [12] .
HBV is an enveloped virus belonging to the Hepadnaviridae family. Its prevalent hepatotropic behaviour is linked to its capacity of recognizing highly heparin sulfate proteoglycans (HSPGs) on the surface of hepatocytes and, through sodium taurocholate cotransporting polypeptide (NTCP or SLC10A1), HBV colonises infected liver cells [13] . Subsequently, HBV partially double-stranded DNA (rcDNA) becomes a completely circular DNA (ccDNA) into the hepatocyte nucleus and it mimics a template for all HBV proteins [14] .
It seems that HBV X protein (HBVx) plays a critical role in the development of HCC activating Wnt/β-catenin signalling and promoting tumor initiation through different antiapoptotic mechanisms [15] . First of them, HBVx inhibits p53-mediated apoptosis and it increases the expression of telomerase reverse transcriptase and telomerase activity, thus prolonging the lifespan of hepatocytes and inducing malignant transformation [16] . Additionally, HBVx truncation contributes to the integration of HBV into the host genome and the c-terminal region produced by its truncation is implicated in the cancerogenesis. As matter of facts, this genomic region induces hepatocytes proliferation, oxidative stress through the production of ROS and it increases the invasiveness and the metastasis HCC-related through the activation of MMP10 by C-Jun signalling [17] [18] [19] [20] . Because of this peculiar ability to integrate into the host genome, control of HBV replication by nucleos(t)ide analogues (NAs: entecavir and tenofovir disoproxil), reduces but doesn't eliminate the risk of HCC in patients with persistent
HBsAg positivity [25] [26] [27] . Therefore, despite of serum HBV-DNA negativization, a strictly surveillance is recommended in order to achieve an early stage HCC diagnosis.
HCV
Globally, HCV prevalence has been estimated at 2.5%, affecting almost 177 million of people worldwide and 10% -20% of HCC diagnosed are HCV infection-related [28] . While HBV infection only chronicizes in 5% -10% of cases, the chronicity of HCV infection occurs in about 85% -90% of patients [29] ( Figure 2 The recent introduction of directly acting antivirals (DAAs) allows achieving a sustained virologic response (SVR) in more than 90% of treated patients, whatever the stage of liver fibrosis. Moreover, the excellent safety profile of DAAs has allowed treatment to a larger number of HCV patients with more advanced liver cirrhosis and a higher risk of HCC [44] . HCV eradication reduces risk of hepatic decompensation and both liver-related and overall mortality, in these subjects [45] . Similarly, the risk of new occurrence and/or recurrence of HCC in patients with advanced liver disfunction or cirrhosis is also significantly reduced but not [50]. Thus, regular surveillance is mandatory amon these patients, even after clinical stabilization and improvement of the fibrosis.
Alcohol
Alcoholic abuse is considered the oldest risk factor for HCC, particularly in the case of heavy consumption (50 -70 gr/die) [5] . tion, additionally to a direct cell injury by DNA damage, lipid peroxidation and tumour necrosis factor (TNF) pathway signalling via nuclear factor kappa B [53] . Further mechanisms include iron overload, decreased vitamin A (retinoid acid) levels and downregulation of S-adenosyn-methionine [54] .
Although alcohol abuse increases the risk of HCC through the development of fibrosis, there is no evidence that highlights its direct cancerogenic potential.
Conversely, different meta-analysis show the synergic actions of alcohol and HBV and HCV infection in the process of fibrosis and progression to cirrhosis with a significant higher rate among those patients with a higher consumption [55] .
Aflatoxin Exposure
Aflatoxins are secondary metabolites of Aspergillus flavus and Aspergillus parasiticus, which are fungus that grow under climatic factors, such as high moisture and temperature, typically of Asia and sub-Saharan Africa. Furthermore, they are common contaminants of food, especially in maize, groundnuts, wheat, soy and rice [56] .
There are several types of aflatoxin and, according to the International Agency for research on cancer, Aflatoxin B1 (AFB1) is the most toxic and carcinogenic of the family [57] . As matter of fact, while AFB1 is absorbed in the enterocytes of the small intestinal epithelium, liver injury is related to the conversion into aflatoxin-8,9-exo-epoxid thru hepatic cytochrome P450. This metabolite is highly reactive with the p53 tumor suppressor gene and it generates mutation at codon 249 that has been observed in more than 50% of HCC cases aflatoxin exposure-related [58] [59]. Subsequently, aflatoxin-8,9-exo-epoxid binds hepatocyte DNA forming procancerogenic adducts that cause further mutations in nucleotides [58] .
It has been observed that areas with high prevalence of HCC-aflatoxin related coincide with areas with endemic HBV infection, suggesting a synergic mutagenic role of HBV and AFB1 and justifying the highest risk among those people exposed to both [60] [61] [62] .
Metabolic Risk Factors for HCC

NAFLD/NASH
NAFLD is the most common hepatic disorder in developed countries, with a prevalence ranging from 6% to 35% [63] ; moreover, it is considered the emerging leading cause of chronic liver disease, with an estimated incidence in Western countries (20% -30%) higher than in Asia (5% -18%) [64] . Additionally, the prevalence of NAFLD is increasing worldwide, depending on the current trends in dietary irresponsibility and preponderance of a sedentary lifestyle and showing a significant linear rise with diabetes and metabolic syndrome [65] . Cur- 
Visceral Obesity
Epidemiological reports demonstrate that overweight and obesity, two rapidly increasing conditions in developed countries and defined by a body mass index (BMI) higher than 25, significantly correlate with an elevated cancer risk [83] [84]. More than 90,000 cancer-related deaths per year in the US are linked to excessive body weight [85] .
Visceral adiposity causes a low grade chronic inflammation with a massive release of pro-inflammatory cytokines. In particular, adipocytes secrete several pro-inflammatory molecules including tumor necrosis factor-alpha (TNFα) and interleukin-6 (IL-6) which are more clearly linked to the progression from NAFLD to NASH and HCC by stimulating pro-oncogenic signal pathways [84] . 
IR/T2DM
Almost 70% of obese patients affected by T2DM develops NAFLD and almost 30% of them progress to NASH, highlighting that T2DM increases risk for cirrhosis and HCC [92] [93] . Large population-based cohort studies showed a 1.86 to 4-fold increase in risk of HCC among patients with diabetes [94] .
As 
Microbiota
Several observations demonstrate that intestinal microbiota (IM) contributes to NAFLD and its status may promote progression to NASH, particularly in obese patients [96] [97].
IM is mainly composed ofat least 500 -1000 different species and trillions of aerobes and anaerobes microorganisms and, although more than 50 bacterial phyla have been detected, it is dominated by the Bacteroidetes and the Firmicutes [98] . The gut bacteria are able to synthesize vitamins and all essential and nonessential amino acids, contributing to biotransformation of bile [99] .
Additionally, they provide the biochemical substrates for the metabolism of host-derivated mucines and nondigestible carbohydrates (large polysaccharides, such as starches, cellulose, hemicellulose, pectins, and gums; some oligosaccharides escaped from digestion; unabsorbed sugars and alcohols from the diet) [100] . These metabolic functions results in the recovery of energy for the host and a supply of energy for the microbiota growth and proliferation. Function and compositionof the IM are influenced by several factors such as age, pH of the intestinal enviroment, high fat diet and probiotics [101] .
Emergent evidences show a strong cross-talk between gut and liver, the so called "gut-liver axis", and it seems that intestinal bacteria are responsible of the maintenance of a healthy axis; furthermore, almost 70% of liver blood 
Polymorphisms
Emergent evidences show that specific gene polymorphisms are determinant fac- PNPLA3, a 481-residue protein, has been identified in various tissues but mostly expressed in the liver, particularly in hepatocytes and hepatic stellate cells, where it explicates hydrolase activity towards triglycerides and retinyl esters, respectively [110] . The cytosine (C) to guanine (G) transversion in rs738409
causes an isoleucine (I) to methionine (M) exchange at amino acid 148 (I148M) with loss of its hydrolysefunction and consequent retention of fat in hepatocytes and retinol in hepatic stellate cells [111] [112] . Additionally, the I148M mutation also reduces very low density lipoproteins (VLDL) secretion and it partially justifies the fat depots in PNPLA3 mutation carriers [113] .
Retention of retinoids in hepatic stellate cells results in cell proliferation and differentiation [112] [114] [115] ; moreover, the detection of a highest lactate-to-pyruvate ratio in patients with PNPLA3 I148M mutation suggests a shift to anaerobic metabolism probably as a consequence of hepatic hypoxia, mitochondrial dysfunction, and oxidative stress [116] . These pathogenic mechanisms could explain the increased risk of progression to NASH and HCC in patients with Met148 PNPLA3 over expression [117] . Two other specific gene polymorphisms, such as TM6SF2 E167K and GCKR rs780094, also seem to be associated with a higher risk of fatty liver and liver fibrosis [72] . These evidences underline the role of steatosis as a strong precancerogenic factor that, in association to genetic environment, could contribute to progression to HCC.
Surveillance
Nowadays, almost 50% of HCC are diagnosed at advanced stage with a poor prognosis and a 5-year overall survival rate lower than 10%. On the contrary, in patients who receive an earlier diagnosis, the 5-year survival rate increases to 70% [117] . As suggested by American Association for the Study of Liver (AASLD) and European Association for the Study of Liver (EASL) guidelines for the management of HCC, the implementation of surveillance by a combination of instrumental investigations such as ultrasounds (US), computed tomography (CT) and/or magnetic resonance imaging (MRI), allows to significantly improve the prognosis thanks to the detection of smaller tumors [118] [119]. The availability of serum biomarkers such as alpha-fetoprotein (αFP) and Protein Induced by Vitamin K Absence or Antagonist II (PIVKA-II) in combination with imaging also contributes to improve the accuracy of screening of hepatic malignancies.
The role of αFP levels in the diagnosis of HCC remains controversial; in fact, despite of elevated αFP levels in 60% -80% of patients with HCC and its usefulness in monitoring of HCC-treated patients, serum αFP values may be influenced by non-neoplastic factors, such as viral infections and cirrhosis [120] [121] [122] ; moreover, low levels of αFP may be detectable in more than 50% of HCC patients, highlighting the poor sensitivity of this biomarker [123] .
PIVKA-II is considered a suitable serum marker of HCC due to its high specificity. Thanks to the development of accurate measuring methods, Japanese So- 
